Disclosure Plus

Exchange Issues Notice Designating RN2 Technologies Co., Ltd. as a Company with Inadequate Disclosure

Shin Ha-yeon
2026-07-24 17:36:46
[Edaily Reporter Shin Ha-yeon ] The KOSDAQ Market Division of the Korea Exchange announced on the 24th that RN2 Technologies Co., Ltd.(148250)has been notified of its impending designation as a company with inadequate disclosure due to a failure to disclose a correction to the resolution to convene a shareholders’ meeting in a timely manner.
The date on which the grounds for the disclosure arose was June 25. The Exchange plans to follow the relevant procedures and decide by August 19 whether to designate the company as a non-compliant discloser and determine the penalty points to be imposed.
RN2 Technologies Co., Ltd. currently has 0 penalty points imposed for non-compliant disclosures over the past year. If the company is ultimately designated as a non-compliant discloser and the penalty points imposed for this incident total 8 or more, trading in its shares may be suspended for one day. If the cumulative penalty points over the past year, including this incident, total 10 or more, the company may be subject to a substantive review of its listing eligibility.

Economy

Corporation

IT·Science

Economy

[Exclusive] Financial Supervisory Service Launches Sudden Investigation into Three Credit Rating Agencies Over “Belated Downgrades”… Scrutinizing JR and Joongang for Neglecting Default Risks

The Financial Supervisory Service (FSS) has launched a surprise on-site investigation into the three major domestic credit rating agencies in connection with the series of defaults by JR GLOBAL REIT a…
2026-09-11 12:12:02

Corporation

'Loresibint Under Review for Approval in the U.K. Following U.S. Approval'… SamilPharmaceutical Gets Green Light to Enter 8 Trillion Won Korean Market

SamilPharmaceutical(000520)With “Lorecivivint,” a new drug for osteoarthritis for which BioSplice holds exclusive domestic distribution rights, entering the regulatory review process in the UK followi…
2026-09-11 10:02:02

IT·Science

GC Biopharma Corp. Receives IND Approval for Phase 2 Clinical Trial of COVID-19 mRNA Vaccine… First Patient to Receive Dose by Year-End

GC Biopharma Corp. Headquarters in Yongin, Gyeonggi Province (Photo: GC Biopharma Corp.) GC Biopharma Corp. will begin Phase 2 clinical trials of its COVID-19 vaccine, which utilizes the company’s…
2026-09-11 14:35:03